investorscraft@gmail.com

Stock Analysis & ValuationNeuroSense Therapeutics Ltd. (NRSNW)

Professional Stock Screener
Previous Close
$0.00
Sector Valuation Confidence Level
High
Valuation methodValue, $Upside, %
Artificial intelligence (AI)n/an/a
Intrinsic value (DCF)n/a
Graham-Dodd Methodn/a
Graham Formulan/a

Company Information

Medinat ha-Yehudim Street 85
Herzliya 4676670
IL
Phone: 972 9 953 1142
Industry: Biotechnology
Sector: Healthcare
CEO: Alon Ben-Noon
Full Time Employees: 17

NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for debilitating neurodegenerative diseases in Israel. Its lead product candidate is PrimeC, a novel oral formulation for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline product candidates include StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.

HomeMenuAccount